$55.17 Million in Sales Expected for Intrexon Corporation (XON) This Quarter

Wall Street brokerages forecast that Intrexon Corporation (NYSE:XON) will post $55.17 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Intrexon Corporation’s earnings, with the highest sales estimate coming in at $60.69 million and the lowest estimate coming in at $51.99 million. Intrexon Corporation reported sales of $48.99 million in the same quarter last year, which indicates a positive year-over-year growth rate of 12.6%. The business is expected to announce its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Intrexon Corporation will report full-year sales of $55.17 million for the current financial year, with estimates ranging from $213.35 million to $236.02 million. For the next financial year, analysts anticipate that the business will report sales of $284.29 million per share, with estimates ranging from $229.25 million to $354.20 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Intrexon Corporation.

Intrexon Corporation (NYSE:XON) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million for the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.42) earnings per share.

XON has been the topic of a number of research analyst reports. BidaskClub raised Intrexon Corporation from a “strong sell” rating to a “sell” rating in a report on Thursday, June 15th. Zacks Investment Research downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Northland Securities set a $30.00 price target on Intrexon Corporation and gave the stock a “buy” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $37.60.

Intrexon Corporation (NYSE XON) opened at 19.37 on Friday. The stock has a 50 day moving average price of $19.56 and a 200-day moving average price of $21.42. Intrexon Corporation has a 12-month low of $17.04 and a 12-month high of $32.90. The firm’s market cap is $2.33 billion.

In other Intrexon Corporation news, Director Robert B. Shapiro bought 2,850 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the transaction, the director now directly owns 43,157 shares in the company, valued at $755,247.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dean J. Mitchell bought 5,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average price of $18.33 per share, for a total transaction of $91,650.00. Following the completion of the transaction, the director now owns 18,103 shares in the company, valued at $331,827.99. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 144,569 shares of company stock worth $2,719,429. 55.10% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in Intrexon Corporation by 60.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after acquiring an additional 54,179 shares during the period. Stifel Financial Corp increased its position in Intrexon Corporation by 15.5% in the 1st quarter. Stifel Financial Corp now owns 60,748 shares of the biotechnology company’s stock valued at $1,209,000 after acquiring an additional 8,135 shares during the period. National Planning Corp increased its position in Intrexon Corporation by 13.4% in the 2nd quarter. National Planning Corp now owns 12,958 shares of the biotechnology company’s stock valued at $316,000 after acquiring an additional 1,528 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in Intrexon Corporation by 3.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 82,670 shares of the biotechnology company’s stock valued at $1,639,000 after acquiring an additional 2,645 shares during the period. Finally, Swiss National Bank increased its position in Intrexon Corporation by 2.2% in the 1st quarter. Swiss National Bank now owns 97,700 shares of the biotechnology company’s stock valued at $1,936,000 after acquiring an additional 2,100 shares during the period. Hedge funds and other institutional investors own 82.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/17/55-17-million-in-sales-expected-for-intrexon-corporation-xon-this-quarter.html.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon Corporation (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply